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ABSTRACT
Objectives Janus kinase inhibitors (JAKi) have 
been approved for use in various immune- mediated 
inflammatory diseases. With five agents licensed, it was 
timely to summarise the current understanding of JAKi 
use based on a systematic literature review (SLR) on 
efficacy and safety.
Methods Existing data were evaluated by a steering 
committee and subsequently reviewed by a 29 person 
expert committee leading to the formulation of a 
consensus statement that may assist the clinicians, 
patients and other stakeholders once the decision is 
made to commence a JAKi. The committee included 
patients, rheumatologists, a gastroenterologist, a 
haematologist, a dermatologist, an infectious disease 
specialist and a health professional. The SLR informed the 
Task Force on controlled and open clinical trials, registry 
data, phase 4 trials and meta- analyses. In addition, 
approval of new compounds by, and warnings from 
regulators that were issued after the end of the SLR 
search date were taken into consideration.
Results The Task Force agreed on and developed 
four general principles and a total of 26 points 
for consideration which were grouped into six 
areas addressing indications, treatment dose and 
comedication, contraindications, pretreatment screening 
and risks, laboratory and clinical follow- up examinations, 
and adverse events. Levels of evidence and strengths of 
recommendations were determined based on the SLR 
and levels of agreement were voted on for every point, 
reaching a range between 8.8 and 9.9 on a 10- point 
scale.
Conclusion The consensus provides an assessment 
of evidence for efficacy and safety of an important 
therapeutic class with guidance on issues of practical 
management.
INTRODUCTION
The therapeutic options for patients with immune- 
mediated inflammatory diseases (IMIDs), such 
as rheumatoid arthritis (RA), psoriatic arthritis 
(PsA), axial spondyloarthritis/ankylosing spondy-
litis (AxSpA/AS), systemic lupus erythematosus 
(SLE), psoriasis (PsO), atopic dermatitis (AD), 
Crohn’s disease (CD), ulcerative colitis (UC) and 
others, have significantly improved over the past 
two decades. This results primarily from the intro-
duction of several novel medications, in particular 
biological (b) disease- modifying antirheumatic 
drugs (DMARDs), as reflected in recent manage-
ment recommendations.1–6 Improved strategic utili-
sation of drugs has similarly impacted positively on 
outcomes.
Among all therapies developed for IMIDs over 
the last two decades, only tumor necrosis factor 
(TNF)- inhibitors exhibit a very broad efficacy 
across many diseases: RA, PsA, axSpA, juvenile 
idiopathic arthritis, PsO, CD, UC and uveitis.7 Even 
though targeting just a single cytokine, no other 
treatment modality has yet been approved for such 
a broad list of indications, suggesting that TNF is 
pathogenetically involved across a diverse range 
of IMIDs. All other biological agents are licensed 
for fewer indications. This will likely change 
with the advent of Janus kinase (JAK)- inhibitors 
(JAKi), a new class of targeted synthetic DMARDs 
(tsDMARDs) that interfere with signal transduction 
pathways of a variety of cytokines and thereby have 
the potential to mediate immune modulatory bene-
fits across a broad range of pathologies and their 
clinical phenotypes.
bDMARDs are usually monoclonal antibodies or 
receptor constructs that target a specific soluble or 
cell surface molecule, either a cytokine, a cytokine 
receptor or another cell membrane antigen. They 
either prevent interaction of the specific ligand with 
its cognate receptor, destroy a specific cell popula-
tion, such as B- cells, or inhibit cross talk between 
particular cell populations. They have to be admin-
istered parenterally since they are proteins. They 
also do not enter the cell but mediate their respec-
tive modes of action outside the cell or via the cell 
surface.
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The pathways that mediate cytokine receptor signal trans-
duction have been elucidated in recent years providing novel 
and rational targets for drug development to modify cytokine 
effector function. Synthetic chemical agents that interfere with 
these pathways have been developed for various indications.8–10 
Among them, the JAKi represent a series of intracellularly active 
drugs, some of which have been approved for the treatment of 
several IMIDs. Five JAKi, tofacitinib, baricitinib, peficitinib, 
upadacitinib and filgotinib, are currently approved for thera-
peutic use in one or more IMIDs in a number of geographical 
regions.
Our experience with bDMARDs spans two decades across 
many diseases with thousands of patient years of experience 
including in registries in many countries. In contrast, data from 
registries are quite limited for JAKi and some have only recently 
been approved by several regulatory authorities; safety data for 
more than 10 years are derived mainly from long term exten-
sions of randomised clinical trials.11 12 Therefore, it was deemed 
important to develop an evidence- based consensus statement 
that focuses on practical issues in the use of JAKi.
Scope and purpose
Recommendations for the management of individual IMIDs 
focus primarily on therapeutic strategies and the general use 
of individual or groups of agents. While quite comprehensive, 
they usually address a particular disease and general issues, only 
rarely accommodating the various, often complex aspects related 
to the general application of an individual drug or a specific 
mode of action. Therefore, consensus statements on the more 
comprehensive use of specific agents or classes of drugs have also 
been developed.13–16 These provide more detailed information 
on efficacy and safety of a class of drugs than in the traditional 
broad management recommendations. Such ‘points to consider’ 
can provide prescribers, like specialists in specific disease areas, 
and patients (especially when information is available for layper-
sons), with an expert opinion on appropriate use of a new drug 
and its place in treatment algorithms. When a drug is approved 
for more than one indication, a specific consensus statement 
can be used across specialties. Thus, the target of the present 
consensus statement comprises rheumatologists, dermatologists, 
gastroenterologists, other health professionals involved in these 
areas, patients with these respective diseases, but also hospital 
managers and representatives of regulators and social security 
agencies.
These points to consider are not meant to suggest a preferen-
tial use of JAKi for any particular disease but rather to provide 
evidence- based information in conjunction with expert opinion 
once an agent of this class has been considered for the treatment 
of a patient with a specific disease for which the drug is indi-
cated. A research agenda will complement these points to drive 
momentum to search for more evidence where this is insufficient 
or lacking. Before addressing the methodology related to this 
document, we will briefly allude to the mode of action and other 
pharmacological aspects of this class of drugs.
Mode of action
JAKs are non- receptor tyrosine kinases associated with the 
cytoplasmic domain of type I and II cytokine receptors which 
are activated when these are engaged by their cognate ligands; 
once phosphorylated, they phosphorylate signal transducers 
and activators of transcription (STATs) which then induce gene 
activation.17 JAKi reversibly inhibit kinase signalling for varying 
periods of the dosing cycle. They are oral small molecules that act 
intracellularly and prevent the phosphorylation of JAKs. Many 
cytokines, such as interleukin (IL)-2, 6, 12, 15 and 23 as well as 
interferons use the JAK- STAT pathways, while others, such as 
IL-1, IL-17 and TNF, do not (figure 1). In addition, haemato-
poietic growth factor receptors, such as those for erythropoietin 
(EPO), thrombopoietin and granulocyte- macrophage colony- 
stimulating factor, use the JAK- STAT pathway (figure 1). Within 
the cell usually different JAK molecules are associated with each 
of these receptor chains, acting in tandem as heterodimers, such 
as JAK1 and JAK2, JAK1 and JAK3 or JAK1 and TYK2. Only in 
the case of haematopoietic growth factor receptors both chains 
carry JAK2. Thus, JAK enzymes - JAK1, 2, 3 and TYK2 - func-
tion as dimers and once activated phosphorylate STATs, which 
subsequently induce gene transcription.
The selectivity of JAKs can be determined by using purified 
enzyme systems and a variety of cellular models.18 19 Varying 
approaches may lead to differing results with respect to perceived 
selectivity of JAKs, and selectivity is dose- dependent, since at 
higher doses the compounds lose selectivity.19 20 The in vivo 
selectivity may differ further so that in vivo markers may also be 
helpful. Reduction of inflammation usually produces an increase 
in haemoglobin, as exemplified by the rapid normalisation of 
anaemia in patients receiving monoclonal antibodies to the IL-6 
receptor.21 Since EPO signals through JAK2 homodimers, failing 
to see an increase in haemoglobin in patients with anaemia of 
chronic disease who experience clinical improvement on JAKi 
therapy suggests an important degree of JAK2 inhibition. Of 
note, failure to increase haemoglobin is not necessarily linked to 
fatigue and rarely a reason to stop a JAKi. Current views on the 
selectivity of JAKi, taking all aspects including clinical ones (such 
as effects on haemoglobin levels) into consideration are provided 
in figure 1. Of note, the totality of in vivo downstream effects 
of JAKi is still insufficiently understood, especially in specific 
disease settings, and an important matter for further research 
activities.
Given that individual JAKs and STATs can be activated by 
more than one cytokine, upregulation and activation of a single 
STAT pathway does not implicate any one particular cyto-
kine in a response and as such our understanding of the hier-
archical contribution of distinct STATs to effector pathways 
remains conjectural. Nevertheless, success and failure of thera-
peutic trials of drugs of known selectivity enable some insights 
into pathogenesis (figure 1). For example, both IL-6 and IL-23 
receptors (R) signal via JAKs; since IL- 6R inhibition does not 
appear efficacious in PsA or PsO, while IL-12 and IL-23 inhibi-
tion is,22–24 this infers that beneficial effects of JAKi may arise by 
inhibiting IL-23 rather than IL-6 signalling. In contrast, IL- 6R 
antibodies, but not anti- IL-12/23 antibodies,25 are efficacious 
in RA and, therefore, JAKi may be assumed to convey efficacy 
by blocking IL-6 rather than IL-12 or 23 signal transduction. 
Moreover, neither IL-12, IL-23 nor IL- 6R inhibition are effi-
cacious in AS,26 27 while JAKi appear to be28; consequently, this 
effect cannot be explained by interference with IL-6, IL-12 or 
IL-23 signal transduction, but rather by inhibition of signal 
transduction of other cytokines captured by JAKi (figure 1). 
However, also inhibition of type I (or type II) interferon signal 
transduction may play a role.29 30 Similar deliberations may be 
made for inflammatory bowel disease, where IL- 6R inhibition 
is not, or only weakly efficacious,31 while IL-12/23 blockade is 
efficacious,32 and for PsO.33 On the other hand, while pan JAKi 
is apparently efficacious in UC but not in CD,34 35 more JAK1 
selective inhibitors (filgotinib, upadacitinib) showed promising 
results in CD,36 37 implying that differences in the pathogeneses 
of these two inflammatory bowel diseases manifest in subtle but 
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functionally important variations in the relative contribution of 
these signalling pathways.38 Finally while TNF does not activate 
the JAK- STAT pathway directly, it might do so indirectly via 
induction of other cytokines, such as IL-6 or type I interferons.39 
This adds further complexity to our understanding of the patho-
genesis of IMIDs.
Thus, JAKi via its mode of action across signal transduction 
of multiple cytokines is efficacious across a range of IMIDs. 
By corollary, this effect has potential safety repercussions (see 
below). Clinical experience with JAKi will likely provide innova-
tive insights to rewrite our understanding of IMIDs.
Among the JAKi currently approved or under study for IMIDs, 
current information on enzyme assays, cellular assays and in vivo 
data (see above note on laboratory test results regarding JAK2 
inhibition, especially anaemia) suggest that at clinically used 
doses tofacitinib is preferentially a JAK 1, 3 and 2 inhibitor; 
baricitinib is primarily a JAK 1 and 2 inhibitor; peficitinib is an 
inhibitor of JAK3 over JAK 1, 2 and TYK2; upadacitinib is a 
JAK1 inhibitor with effects on JAK2, and filgotinib is primarily a 
JAK 1 inhibitor (figure 1).40 As mentioned above, the preferen-
tial selectivity is dose- dependent and decreases with increasing 
doses as their common mechanism is to prevent ATP- mediated 
protein tyrosine kinase phosphorylation (although a specific 
TYK2 selective inhibitor is also under development that inhibits 
signal transduction by stabilising the pseudokinase domain of the 
protein).41
METHODS
The expert committee adhered to the EULAR standard oper-
ating procedures for the development of recommendations.42 A 
steering committee comprising 15 members and an expanded 
Task Force consisting of 14 additional individuals invited based 
on their expertise and availability and including two patient 
research partners (MdW, MV) and a health professional (MS- M) 
as well as a dermatologist (W- HB), a gastroenterologist (MT), 
a haematologist/haemostaseologist (KG), an infectious disease 
specialist (KLW) and a fellow who performed the systematic 
literature review (SLR) (AK), evaluated the available data. The 
clinicians were all experienced in the treatment of chronic 
inflammatory diseases, had participated in clinical trials of JAKi 
and/or bDMARDs, and several had long- standing experience in 
patient outcomes research and prior consensus statement devel-
opment. The patients and health professionals all had experience 
in consensus activities. There was a broad global representation 
from European countries, Asia, Australia, Latin America and 
North America. All task force members declared their potential 
conflicts of interest and had ongoing opportunity to declare if 
they felt conflicted throughout the process.
Drugs that had not yet undergone regulatory assessment 
or formal approval but for which evidence from clinical trials 
was available, could be considered in the recommendations to 
anticipate potential future uptake in clinical practice, with all 
Figure 1 Depiction of cytokines that activate and drugs that target Janus kinases (JAKs) presumably involved in the pathogenesis of immune- 
mediated inflammatory diseases (IMIDs). Top: efficacy of agents targeting specific JAK- inducing cytokines in different IMIDs. Centre: cytokines and 
respective receptors that trigger JAKs, types of JAKs activated and type of STATs (signal transducers and activators of transcription) activated by the 
respective JAKs. Bottom: JAK- inhibitors which are currently approved for IMIDs and their overall (including clinically derived) selectivity and presumed 
interference (+ or -) with certain cytokine pathways. axSpA, axial spondyloarthritis; EPO, erythropoietin; GM- CSF, granulocyte- monocyte colony 
stimulating factor; IBD, inflammatory bowel diseases; IFN, interferon; IL, interleukin; ND, not done; PsA, psoriatic arthritis; PsO, psoriasis; R, receptor; 
RA, rheumatoid arthritis; TP, thrombopoietin.19 40 146 147
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respective caveats that may emerge during the approval process. 
Indeed, during the time of writing or revising the manuscript 
(and thus after the face- to- face meetings), two drugs, upadac-
itnib and most recently filgotinib, were approved (at least in 
some regions), confirming the validity of the conclusions drawn 
on these agents in the course of the process developing the 
consensus statement.
The steering committee and the fellow (AK) initially discussed 
the research questions for the SLR which was then performed 
accordingly by searching the totality of the respective clinical 
trial literature until end of December 2018 in Medline, Embase, 
Cochrane and 2018 EULAR and ACR abstracts. The details of 
the SLR are published separately.43 Cochrane risk of bias tool 
was used. The SLR addressed RA, PsA, PsO, AS, systemic lupus 
erythematosus (SLE), UC, CD, alopecia areata (AA)/alopecia 
universalis, and atopic dermatitis (AD).
The results of the SLR were first presented to the steering 
group which developed a list of proposed recommendations 
and/or topics to be addressed by the whole task force. The SLR 
and the list prepared by the steering group were then presented 
to the task force which met end of March 2019. Efficacy aspects 
were discussed by the whole task force with input from experts 
in respective fields. The Task Force was split into four breakout 
groups. One group addressed screening, the second monitoring, 
the third contraindications and the fourth adverse effects. Repre-
sentatives of each breakout group reported the results of the 
deliberations and presented proposals for the wording of indi-
vidual points to the whole task force which discussed them in 
detail before voting took place.
For a general principle or point of consideration to be 
accepted for the final document without further change, a 
majority of 75% of the votes was required in the first ballot. If 
this result was not achieved, the respective text was amended 
and subjected to a second ballot, for which a 67% majority was 
required. If this ballot was not successful, further changes were 
proposed until a≥50% majority was attained (or the proposal 
rejected). The points to consider are presented in the wording 
they were finally voted on (table 1). The results of the respec-
tive last ballot are shown as percentage of present members 
in table 1. Notes captured the contents of the discussions and 
the reasoning behind each decision to be presented in the 
comments accompanying the individual items in the manuscript. 
Data which emerged after the voting process, such as material 
made public by regulators, were taken into consideration in the 
manuscript to provide the readers with up- to- date information. 
After the face- to- face meeting, the points to consider as agreed 
by the task force received a final adjudication in terms of level 
of evidence and strength of recommendation. They were finally 
subjected to an anonymous vote (by email) on the levels of agree-
ment. Each recommendation received an adjudication on a scale 
of 0–10, 0 meaning no agreement whatsoever and 10 absolute 
agreement. The draft of the manuscript was sent to all task force 
members for their comments which were all considered for the 
final version prior to submission of the manuscript.
RESULTS
General principles
The task force agreed on four general principles (table 1). The 
first of these refers to the importance of shared decision making 
between the patient and the specialist, including information on 
the benefits and risks of JAKi which is highlighted as principle A. 
This is in line with various management recommendations but 
needs to receive special emphasis when a drug or class of medi-
cines is new and long- term experience is still lacking.
The task force further recommends to use these points- to- 
consider together with general management recommendations 
for the individual diseases which are usually provided by the 
respective international or national societies (item B) and also to 
refer to the product information related to the specific disease to 
be treated (see below item D).
At outset, the task force decided not to provide ‘recommen-
dations’ for the use of JAKi in treatment algorithms, but rather 
‘points to consider’ assisting the clinician when thinking of 
starting, or having decided to start treatment with a JAKi (prin-
ciple C). Recommendations may be seen as too directive and 
would have to be brought into the context of other medications 
and general treatment strategies and adjusted as new informa-
tion comes to hand in a rapidly evolving therapeutic area. In 
contrast, the task force saw its role in elucidating important 
aspects that should be taken into account when thinking of the 
prescription of a JAKi. To this end, general principles as well as 
specific considerations are highlighted as an adjunct to product 
information (principle D).
Individual points
Six major groups of consideration are highlighted (table 1): indi-
cations; dosage and comedications; contraindications; pretreat-
ment screening and risks; adverse events; and laboratory and 
clinical follow- up. The order within these groups does not relate 
to any ranking by importance but occurred either by chance or 
some rationale- based approach to therapies in general.
I. Indications
JAKi have proven efficacious with acceptable safety in patients 
with a variety of IMIDs. They have received regulatory approval 
for patients with RA, PsA and UC who have failed prior conven-
tional synthetic DMARD (csDMARD) or bDMARD therapy, 
and an approval is being sought in further indications, such as 
dermatological, and interferonopathies. Approval of additional 
JAKi for IMIDs is expected. At present, individual JAKi have 
been approved for different diseases and at varying doses, as 
detailed below.
Treatment dose and comedications in different IMIDs
Treatment doses and comedications may differ between indica-
tions (see below) and may have to be adjusted with higher age 
and organ (hepatic, renal) function impairment. Once the ther-
apeutic target (such as remission) is reached, dose reduction or 
increase of intervals between doses may be considered; this dose 
adjustment is not within the label of the JAKi, but similar dose 
changes outside the label have been suggested for bDMARDs 
in various recommendations.44 45 In the following, we will 
address these aspects for the individual IMIDs for which JAKi 
are approved or may be licensed in the future.
Rheumatoid arthritis
Addition of a JAKi to continued methotrexate (MTX) or 
other csDMARDs should be considered if the patient tolerates 
the csDMARD,44 since—just like for all bDMARDs—there 
is evidence for better efficacy of combination compared with 
monotherapy, clinically and/or structurally.46 47 Monotherapy 
of JAKi compared with MTX monotherapy in MTX naïve RA 
patients failed to show significant structural (though not clinical) 
superiority for baricitinib47 and—for the primary endpoint—
failed to show clinical (though not structural) superiority for 
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filgotinib,48 while combination therapy achieved significant 
superiority across all outcomes. On the other hand, mono-
therapy of tofacitinib and upadacitinib in MTX naïve patients 
had significantly better clinical and structural efficacy than MTX 
monotherapy,49 50 but neither was investigated in 3- arm trials 
with an additional combination arm. In contrast, filgotinib was 
Table 1 Points to consider for the treatment of patients with immune mediated inflammatory diseases with Janus kinase (JAK) inhibitors
Item Wording LoE SoR Vote (%) LoA
General principles*
A Initiation of JAK- inhibitor therapy and the treatment target to be achieved should be based on a shared decision between the patient and 
the medical specialist, which requires full information of the patient on the potential benefit and risks of this therapy.
n.a. n.a. 100 10
B Therapeutic approaches to treating patients with chronic inflammatory conditions should be in line with international and national 
recommendations (algorithms) for the management of the respective disease.
n.a. n.a. 92 9.5
C The points to consider when initiating JAK- inhibitor therapy do not provide information on when JAK- inhibitors should be used in the 
treatment algorithm, but rather attempt to assist the clinician once the decision to prescribe a JAK inhibitor has been made.
n.a. n.a. 92 9.8
D These points to consider address specific (but not all) aspects related to the application of JAK- inhibitor therapy and the clinician should 
additionally refer to the disease- specific product information.
n.a. n.a. 88 9.8
Individual points*
I Indications
1 Patients with immune mediated inflammatory diseases (IMIDs) who have failed prior conventional and/or biological therapies; as of 2019, 
these include rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis (UC).
1a A 100 9.7
2 Currently, there is no direct evidence of superiority regarding efficacy or safety of one JAK- inhibitor over another one. 5 D 88 9.8
II Treatment dose and comedications in different IMIDs
1 Use the dose recommended for the specific disease 1a A 100 9.6
2 Consider dose adjustments in patients with higher age (>70 years), significantly impaired renal or hepatic function and/or risk of drug- 
interactions, or as a result of other comorbidities, as per individual product information.
2b/5 C/D 100 9.7
3 Regarding comedication, follow specific recommendations for the respective disease; in RA consider adding a JAK inhibitor to continued 
csDMARDs, if the patient tolerates the csDMARD
1a A 92 9.1
4 Consider dose reduction of the JAK inhibitor in RA patients in sustained CDAI or Boolean remission on background csDMARDs. 1b A 77 9
III Contraindications (consult also label and warning, see general principle D)
1 Severe active (or chronic) infections, including TB and opportunistic infections. 2b/5 B/D 100 9.9
2 Current malignancies. 5 D 80 9.2
3 Severe organ dysfunction, such as severe hepatic disease (Child- Pugh C) or severe renal disease. 5 D 100 9.9
4 Pregnancy and lactation. 5 D 100 9.9
5 Recurrent VTE (unless anticoagulated) 5 D 93 8.8
IV Pre- treatment screening and risks
1 Patient history and physical examination. 5 D 100 9.9
2 Routine laboratory testing (full and differential blood counts, liver tests (transaminases), renal function; lipid levels at approximately 3 
months after initiation of therapy (and possibly at baseline unless measured within the last 12 months); no CPK testing recommended.
2b/5 B/D 80 9.3
3 Hepatitis B testing (hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, and with/without HBV DNA testing 
as discussed in text). Hepatitis C testing (hepatitis C antibody, with HCV RNA testing if antibody positive)
5 D 92 9.8
4 Human immunodeficiency virus testing in high- risk populations 5 D 100 9.9
5 TB screening as per national guidelines 2b B 96 9.9
6 Assess and update vaccination status. 5 D 100 9.9
7 Consider risk factors for VTE, especially a past history of VTE. 5 D 96 9.9
V Adverse events
1 Serious infections (similar to bDMARDs), opportunistic infections including TB, Herpes zoster* (increased rates compared to bDMARDs); the 
risk of infectious events can be lowered with reduction or elimination of concomitant glucocorticoid use.
2b B 100 9.9
2 Rates of malignancy do not appear elevated with JAK inhibition, although the risk of NMSC may be elevated. 2b B 95 9.6
3 Lymphopenia, thrombocytopenia, neutropenia, anaemia may occur. 2b B 100 9.8
4 An increased risk of VTE has been reported in a safety trial of RA among patients using 10 mg two times a day tofacitinib and within the 
placebo- controlled trial period of baricitinib in patients with RA.
2b B 94 9.5
5 Elevations of CPK are noted with JAK inhibitors but have not been associated with clinical events. Elevations of creatinine have been noted 
with JAK inhibitors but have not been associated with renal failure or hypertension.
2b B 94 9.5
VI Laboratory and clinical monitoring during follow- up.
1 Minimal laboratory monitoring: full and differential blood counts and liver transaminase tests at 1 and 3 months and then periodically, 
such as every 3 months; lipid levels only at month 3.
2b/5 B/D 92 9.4
2 Annual skin examination (for detection of skin cancer). 5 D 83 8.3
3 Evaluate response using validated, disease- specific measures of disease activity; for evaluation and definition of response, be aware that 
CRP and ESR may be reduced independently of reduction of disease activity and possibly even in infections.
2b/5 B/D 95 9.8
These bullet points have been agreed on as abbreviated summaries of the discussions and the explanatory text to each of these items should be regarded as an integral part of these points.
*These points are a short abbreviation of the items discussed and presented in detail in the body of the text. They should not be applied independently of the information provided there in 
more detail, but present only an overview of the general scope of the consensus statement. The percentages shown reflect the proportion of participants who approved the respective bullet 
point during the voting at the task force meeting. Some items carry two levels of evidence, because part of the respective points have only the level of expert opinion (level 5), namely II/2: 
comorbidities not studied, since most excluded from trials; III/1: patients with chronic infections (even if mild) were not studied; IV/2and VI/1: proposed intervals not studied; VI/3 blunting of 
the acute phase response during infections not sufficiently studied.
bDMARD, biological disease- modifying antirheumatic drug; CDAI, Crohn’s Disease Activity Index; CPK, creatine phosphokinase; CRP, C reactive protein; csDMARD, conventional synthetic 
disease- modifying antirheumatic drug; HBV, hepatitis B virus; HCV, hepatitis C virus; LoA, levels of agreement; LoE, level of evidence; n.a., not available; NMSC, non- melanoma skin cancer; 
SoR, strength of recommendation; TB, tuberculosis; VTE, venous thromboembolism.
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assessed in a 3- arm trial in MTX- naive RA patients; while at 
both the 100 mg and 200 mg dose filgotinib plus MTX attained 
the primary endpoint of superiority against MTX monotherapy, 
filgotinib monotherapy at 200 mg failed to show statistical supe-
riority compared with MTX monotherapy (filgotinib 100mg as 
monotherapy was not tested), 1 48 None of the JAKi has ever been 
compared with MTX plus glucocorticoids, the standard therapy 
recommended by EULAR for over a decade44 which has not been 
shown to be inferior to bDMARDs plus MTX.51 52 However, 
a JAKi can be given as monotherapy in case of intolerance or 
contraindications to MTX and other csDMARDs.
The recommended dose of tofacitinib for RA is 5 mg two 
times a day in most countries; at this dose tofacitinib was supe-
rior to placebo in patients with active disease despite MTX or 
prior bDMARD therapy, and in a head to head study tofacitinib 
5 mg two times a day combined with MTX was non- inferior (but 
not superior) to adalimumab combined with MTX while mono-
therapy of tofacitinib 5 mg two times a day failed to show non- 
inferiority to either combination therapy with tofacitinib plus 
MTX or adalimumab plus MTX.46 Of note, according to infor-
mation by regulatory authorities tofacitinib at 10 mg two times 
a day was associated with an increased venous thromboembo-
lism (VTE) and pulmonary embolism (PE) rate in patients with 
RA enriched for cardiovascular risk factors,53 54 and a similar 
warning was also issued for 5 mg two times a day55 (see also 
below). In addition, the dose should be reduced in patients with 
a creatinine clearance (CrCl) of <30 mL/min and is contraindi-
cated in patients with severe hepatic impairment (Child Pugh C).
The recommended dose of baricitinib in RA is 4 mg once daily 
(except for some countries such as USA, Canada and China, 
where it is 2 mg daily). At the 4 mg dose in combination with 
MTX, it showed superior efficacy to placebo (or de novo MTX) 
in all RA patient populations, MTX/csDMARD- insufficient 
responders (IR), bDMARD- IR or MTX- naïve, respectively; in 
most countries the approval is for these populations apart from 
MTX- naïve patients, as combination therapy or monotherapy. 
A dose of 2 mg once daily is appropriate for patients aged ≥75 
years, those with a CrCl of 30–60 mL/min and may be appro-
priate for patients with a history of chronic or recurrent infec-
tions. In a head to head study baricitinib 4 mg per day combined 
with MTX had superior efficacy compared with adalimumab 
40 mg combined with MTX.56 Subanalyses revealed that this 
superiority was primarily seen for patient reported outcomes, 
but not for joint counts. In a tapering study patients in long- term 
low disease activity or remission after 15 months therapy could 
reduce baricitinib to 2 mg per day; low disease activity (LDA) was 
maintained at 12 weeks after step down in 83% of patients; 90% 
of those who flared regained their original response after dose 
increase.57 Combination of baricitinib with MTX had signifi-
cantly better structural outcomes compared with MTX alone, 
but—while monotherapy was similar to combination therapy 
in terms of clinical and functional outcomes—structural benefit 
was not significant for baricitinib monotherapy.47
Since the date of the SLR, upadactinib has been approved by 
FDA and EMA at 15 mg daily. At this dose, it showed superior 
efficacy to placebo (or de novo MTX) in all RA patient popu-
lations, MTX- IR, bDMARD- IR or MTX- naïve, respectively. In 
most countries, the approval is for these populations except for 
MTX- naïve, as combination therapy or monotherapy. A upadac-
itinib monotherapy study in patients with IR to MTX had high 
response rates but lacked a comparator group of upadacitinib 
combined with MTX.49 In combination with MTX, upadaci-
tinib 15 mg provided superior efficacy compared with adalim-
umab plus MTX in a head to head study.58 As in the study of 
baricitinib versus adalimumab, subanalyses revealed that this 
superiority was primarily seen for patient- reported outcomes, 
but not for joint counts.58 No dose adjustment is needed for 
renal impairment, but with severe hepatic impairment the drug 
is contraindicated.
More recently, filgotinib was approved at 100 mg and 200 mg 
doses in Europe59 and in Japan. In contrast, FDA did not 
approve filgotinib wishing to await data from spermatogenesis 
safety studies and raising concern about the safety of the 200 mg 
dose.60 Filgotinib has completed phase 3 clinical trials at 100 mg 
and 200 mg daily. Data of a study comparing filgotinib plus MTX 
head to head with adalimumab plus MTX recently became avail-
able and revealed non- inferiority for DAS28- C reactive protein 
(CRP) <3.2 for the 200 mg, but not the 100 mg dose; it was not 
possible to claim superiority versus adalimumab plus MTX due 
to the statistical plan.61 Filgotinib has also been studied as mono-
therapy (see above).
Peficitinib showed significant efficacy on symptoms, signs and 
structural outcomes of RA in randomised trials including mono-
therapy and concomitant MTX treatment, in patients with an 
IR to TNFi and an open label study with etanercept as a safety 
control. These studies included a majority of Japanese, Korean 
and Taiwanese patients,62 63 while the difference to placebo was 
small in a global study where very high placebo response rates 
were seen.64 Peficitinib is approved in Japan and Korea at 100 
and 150 mg daily.
The dose of JAKi should be modified according to patient- 
specific demographics, comorbidities and/or concomitant medi-
cations as per product monograph inserts (see also section on 
contraindications).
There is no evidence at present that one JAKi is more effica-
cious clinically, functionally or structurally or safer than another 
JAKi. While two studies have shown superior efficacy of a JAKi 
plus MTX compared with an anti- TNF plus MTX,56 58 two 
other trials have failed to show such effect46 61; moreover, in the 
trials showing superiority of a JAKi plus MTX to adalimumab 
plus MTX, the significantly better efficacy was seen for most 
outcomes, but not for tender and swollen joint counts.56 58 Thus, 
the relevance of this finding is currently limited; moreover, as of 
now, no study compared one JAKi with another. On the other 
hand, several of the above cited studies clearly revealed that JAKi 
have superior efficacy than TNFi for pain and fatigue, an aspect 
that deserves further investigation, as it may relate to a hitherto 
insufficiently recognised and specific mode of action for this 
drug class.
No studies are yet available in JAKi IR or intolerant patients 
switching from one JAKi to another JAKi. However, a recent 
study showed efficacy of anti- TNF therapy after IR to a JAKi,65 
and safety regarding switch from a bDMARD to a JAKi without 
washout, information that was missing hitherto.
Regarding dose reduction in patients with RA in sustained 
Clinical Disease Activity Index (CDAI) or Boolean remission on 
background csDMARD, trial evidence is currently confined to 
dose reduction for baricitinib.57
Psoriatic arthritis
Currently, only tofacitinib is approved for PsA; the licensed dose 
is 5 mg two times a day. The clinical trials demonstrated efficacy 
in patients with prior IR to csDMARDs66 and TNFi.67 The effi-
cacy in PsO is described below.
Since the closing date of the SLR, two phase 3 trials of upad-
acitinib were completed successfully, showing efficacy regarding 
main outcomes of PsA, also when compared with adalimumab 
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(non- inferiority for the ACR20 response with the 15 mg and 
superiority with the 30 mg dose).68 69
Filgotinib at 200 mg daily showed efficacy in a phase 2 trial70 
and phase 3 data are awaited.
Ankylosing spondylitis
Tofacitinib demonstrated significant efficacy at 12 weeks for 
signs and symptoms in patients with highly active AS (by modi-
fied New York criteria) refractory to NSAIDs in a phase 2 dose- 
ranging placebo- controlled RCT. The highest Assessment of 
SpondyloArthritis international Society (ASAS) 20 response was 
observed at 5 mg two times a day, especially in patients with both 
elevated CRP and evidence of MRI inflammation in the sacro-
iliac joints.71 A dose- dependent effect for clinical response was 
not evident. Separation from placebo was observed at 4–8 weeks 
suggesting a slower onset of response than seen with TNFi.
Filgotinib at 200 mg once daily has been assessed in patients 
with active AS refractory to NSAIDs and TNFi (10%) in a 
12 week phase 2 placebo- controlled RCT.28 Significant benefit 
for disease activity, assessed by the AS Disease Activity Score 
(ASDAS), was evident by week 1 and major improvement in 
ASDAS was noted in 33% versus 2% of patients on filgotinib and 
placebo, respectively, at 12 weeks. For most outcomes separation 
from placebo was observed at 4–8 weeks.
Upadacitinib at 15 mg daily was assessed in a 12- week phase 
2/3 placebo- controlled trial that recruited patients with active AS 
refractory to NSAIDs.72 Significantly more patients had an ASAS 
40 response at week 14 in the upadacitinib versus the placebo 
group (52% vs 26%) and this was observed at the first post-
baseline visit at week 2. Other outcomes including MRI spine 
and sacroiliac joint inflammation, were also superior for upadac-
itinib, just like for tofacitinib and filgotinib.
Overall, the 12- week phase 2 data support the efficacy of 
JAKi for a variety of disease outcomes relevant to AS to a degree 
comparable to TNFi while the pattern of AEs and changes in 
laboratory outcomes were similar to those reported in previous 
studies in other indications.
Dermatological diseases including PsO
Nine different JAKi and three selective TYK2 inhibitor have 
been evaluated in PsO; none of them has been approved for this 
indication to date except for occasional individual countries, 
such as Russia (tofacitinib).
Tofacitinib was tested in one phase II, four phase III and one 
long- term extension study, the results of which were recently 
summarised.73 Tofacitinib 5 and 10 mg two times a day showed 
superiority over placebo for all efficacy endpoints at week 16, 
with response maintained for 52 weeks of continued treat-
ment. The Psoriasis Area and Severity Score (PASI) response, 
however, appeared numerically lower than that typically seen 
for bDMARDs such as IL-12/23 or IL-17 inhibitors. Tofacitinib 
improved patients’ quality of life and was well tolerated. With 
the exception of herpes zoster, rates of safety events of interest 
were similar to those in the published literature and health-
care databases for other systemic PsO therapies. Tofacitinib 
10 mg two times a day demonstrated greater efficacy (PASI75 
at 12 weeks: 43% in MTX- IR and 21% in TNFi patients) than 
5 mg two times a day. An additional phase IIa study evaluating 
topical application of tofacitinib in mild- to- moderate PsO found 
significant clinical improvement over placebo treatment after 4 
weeks.74
Baricitinib was studied in a phase IIa dose- ranging study, 
using once daily dosing over 12 weeks. A statistically significant 
difference among patients exhibiting at least a 75% improve-
ment in their PASI (PASI75) when compared with placebo was 
observed for patients receiving 8 or 10 mg daily (43% and 54% 
vs 17%),75 a much higher dose than approved for RA and, again 
even at this dose the skin response is numerically lower than 
reported for several of the more recently approved bDMARDs; 
for example, for IL-12/23 inhibitors the PASI75 amounted to 
about 70% and 80% for ustekinumab and guselkumab, respec-
tively,.76 77 and to 89% on IL-17 inhibition.78
For the JAK1 inhibitors abrocitinib, itacitinib and GSK2586184 
as well as the JAK1/3 inhibitor peficitinib, data in the public 
domain are equally available from one phase II study each. 60% 
of patients receiving the most effective dose regimen (200 mg 
twice daily) of abrocitinib experienced a 75% improvement of 
the PASI.79 Itacitinib showed significant improvement in the 
Physician Global Assessment (PGA) after 4 weeks of treatment 
with 600 mg once daily versus placebo,80 while GSK2586184 
at 400 mg once daily yielded a 75% PASI improvement in 57% 
of patients after 12 weeks,81 and patients treated with 50 mg of 
peficitinib once daily benefitted from improved PASI, PGA and 
reduced body surface area affected.82
Another JAKi, ruxolitinib, was tested in two topical formu-
lations containing 1% and 1.5% of ruxolitinib, respectively, 
versus placebo and two active comparators, namely calcipot-
riene 0.005% cream and betamethasone doproprionate 0.05% 
cream. A statistically significant difference versus the vehicle 
was observed after 4 weeks of treatment for the ruxolitinib 1% 
group, with comparable efficacy of ruxolitinib formulations with 
the active comparators.83
For two additional JAKi, no peer- reviewed publicly available 
data have been published so far.
Finally, a phase II study evaluating the TYK2 inhibitor 
BMS-986165 was recently published.41 Doses ranging from 3 mg 
every other day up to 12 mg daily were studied and compared 
with placebo. BMS-986165 at doses of 3 mg daily and higher 
was found to result in greater clearing of PsO than did placebo 
over a period of 12 weeks, with PASI75 responses up to 75% in 
the highest dose group. Data for two additional TYK2 inhibitors 
await peer- reviewed publication.
Evidence for therapeutic efficacy of JAK- inhibitors or TYK2- 
inhibitors has also been suggested in several other immune- 
mediated inflammatory dermatoses, including atopic dermatitis, 
alopecia areata, vitiligo,84 palmoplantar pustulosis and a case of 
a mucocutaneous disease called idiopathic erythema multiforme 
associated with a mutation in TRPS1 and JAK- STAT activation.85
Taken together, PsO belongs to a group of chronic inflam-
matory skin diseases for which inhibition of JAKs or TYK2 has 
shown clinical efficacy. However, the extent of efficacy observed 
and the safety profile of the JAKi has so far not led to drug 
authorisation by EMA or FDA, but there is considerable interest 
around TYK2 inhibition, given the absence of some safety issues 
linked to non- selective JAKi, as well as regarding indications 
other than PsO, namely AD, where there are still far less options 
available for systemic therapies.
Inflammatory bowel disease
Tofacitinib is indicated for the treatment of adult patients with 
moderately to severely active UC who have had an inadequate 
response, lost response or were intolerant to either conventional 
therapy or a biologic agent.34 Tofacitinib 5, 10 and 15 mg two 
times a day showed significant efficacy for remission (Mayo 
score) in patients who were cs- and bDMARD- IR.86 The recom-
mended dose is 10 mg given orally twice daily for induction for 8 
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weeks (or 16 weeks if adequate benefit is not achieved) and 5 mg 
given twice daily for maintenance (in TNFi- IR patients 10 mg 
two times a day maintenance may be used). The 10 mg two times 
a day dose was associated with VTEs and PEs in patients with 
RA53 (see also below).
Upadacitinib and peficitinib similarly have shown efficacy in 
phase 2 trials in csDMARD and bDMARD- IR patients in dose- 
ranging studies of UC.87 88
In CD, tofacitinib at 5–15 mg two times a day has shown no 
significant efficacy in induction and maintenance of Crohn's 
disease activity index remission (<150) compared with 
placebo.35 However, selective JAK1 inhibition by filgotinib 
showed increased remission rates in patients with moderate to 
severe CD.36 Moreover, upadacitinib also showed promising 
results in a phase II trial in CD37 and larger phase III trials have 
been initiated. Collectively, these findings hold promise for these 
agents as clinical therapeutics in IBD which await corroboration 
in ongoing phase III trials.
Other diseases
Baricitinib was investigated in a phase 2 trial of systemic lupus 
erythematosus and demonstrated significant efficacy at 4 mg but 
not 2 mg compared with placebo.89
Other indications for which JAKi are being evaluated include 
non- infectious uveitis, CANDLE syndrome and other inter-
feronopathies, including USP18 deficiency.90–92 The reader is 
referred to the SLR manuscript.43
II. Treatment dose and comedication 
1. Use the dose recommended for the specific disease.
The dosing of individual JAKi in the various diseases has been 
addressed in the previous section (see above).
 
2. Dose adjustments due to drug interactions 
Tofacitinib is metabolised by the hepatic cytochrome P (CYP) 
450 pathway which leads to drug interactions with inhibitors 
such as ketoconazole and promoters such as rifampicin, neces-
sitating dosage adjustments, although it is also 30% renally 
excreted. In contrast, baricitinib is 70% renally excreted. Filgo-
tinib is metabolised by hepatic carboxylesterases and has a major 
metabolite GS-829845 which is a pharmacologically active, 
selective inhibitor of JAK1, but is 10–20 times less potent than 
the parent compound. Upadacitinib predominantly undergoes 
hepatic oxidation with minor CYP metabolism and peficitinib 
undergoes hepatic conjugation. Organic anion transporter 3 
inhibitors, such as probenecid, interact with baricitinib requiring 
a dose reduction to 2 mg per day (with normal renal function). 
Rifampicin when used in latent tuberculosis (TB) prophylaxis 
or therapy for active TB increases hepatic metabolism of tofaci-
tinib and upadacitinib so that a dose increase of the latter has to 
be considered. Ketoconazole has the opposite effect, inhibiting 
tofacitinib and upadacitinib metabolism so a dose reduction is 
suggested. Dose adjustments due to hepatic or renal impairment 
are discussed below.
The dosing of the individual agents and their metabolisation 
are summarised in table 2.
3. Comedication
Comedication has been addressed in the previous section, 
including addition of JAKi to pre- existing csDMARDs as combi-
nation therapy.
4. Consider dose reduction in sustained remission on back-
ground therapy
This aspect has also been addressed in the previous section. 
For dose adjustments due to impaired organ function see below.
III. Contraindications that should be considered
Contraindications are primarily related to the adverse event and 
the pharmacokinetic/pharmacodynamic profile of the various 
JAKi.
1. Severe active infections, acute or chronic, including latent 
TB and opportunistic: these infections can be seen in pa-
tients treated with JAKi.93 Serious infection rates in RA and 
PsA studies of tofacitinib, baricitinib and upadacitinib were 
comparable to adalimumab with higher rates occurring at 
higher doses.12 93 Tofacitinib treated RA patients above 65 
years (with cardiovascular risk factors) exhibited a higher 
rate of serious infections compared with TNFi treated pa-
tients and according to EMA tofacitinib should be used in 
these patients only if there is no other alternative.94 A recent-
ly published post hoc analysis of RA trial data that included 
an adalimumab comparator found similarly increased risks 
for serious infections among the elderly, particularly among 
those using 10 mg two times a day tofacitinib. Risk elevations 
as compared with younger patients were similar for those 
using adalimumab and tofacitinib 5 mg two times a day, but 
several fold higher for those using 10 mg two times a day.95
2. Malignancy: using a JAKi in this situation should be a shared 
decision with the patient given timing of past malignancy, 
uncontrolled malignancy or ongoing treatment with chemo-
therapy including checkpoint inhibitors. Thus far, patient 
registries and clinical trial data have demonstrated no ma-
lignancy signal. There are no data to suggest that prior ma-
lignancy is problematic with JAKi therapy, but most studies 
excluded patients with malignant disease up to 5 years prior 
to enrolment.
3. Severe organ dysfunction: With severe hepatic disease (Child- 
Pugh C), JAKi should not be used. With respect to severe 
renal disease (CrCl) <30 mL/min), a reduction in dosage is 
recommended for tofacitinib to 5 mg once daily; baricitinib is 
not recommended if CrCl is <30mL/min. With CrCl 30–60 
mL/min baricitinib should be used at 2 mg daily. No dosage 
reduction is currently recommended for other JAKi.
Table 2 Dosing and metabolisation of the different Jakinibs
Drug Dosage
Approved 
indications Metabolism
Tofacitinib RA, PsA: 5 mg bd,
11 mgs ER daily;
UC: 10 mg two 
times a day
RA, PsA, UC CyP3A4;
30% renal excretion
Baricitinib 2 or 4 mg daily RA >66% renal excretion
Upadacitinib 15 mg daily RA CyP3A4;
20% renal excretion
Filgotinib 100 or 200 mg 
daily
RA CES2 ; active metabolite 
1:10 potency
Peficitinib 100 or 150 mg 
daily
RA NNMT, SULT2A1;
16% renal excretion
Ruxolitinib 5–25 mg two times 
a day
Polycythaemia rubra 
vera
Myelofibrosis
CyP3A4, CyP2C9
CES2, carboxylesteraseisoform 2; Cyp, cytochrome P; ER, extended release 
; NNMT, nicotinamide N-methyltransferase; PsA, psoriaticarthritis; RA, rheumatoid 
arthritis; SULT2A1, sulfotransferase 2A1; UC, ulcerative colitis.
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4. Pregnancy and lactation: Limited data are available and con-
traception while taking JAKi is advised for both female and 
male patients in the absence of adequate data. Tofacitinib has 
been shown to be teratogenic in rats and rabbits, and to af-
fect parturition and peri/postnatal development.96
Filgotinib reduces spermatogenesis in a dose- dependent 
manner in animal studies; to date, this has not been observed 
in humans, but a definitive study evaluating this question is 
currently underway97 so this can then be taken into account 
appropriately in male patients.
These agents have short plasma half- lives but a gap of 4 
weeks is recommended after the last dose if future pregnancy 
is being contemplated. It is not known whether tofacitinib is 
secreted in human milk, but it is secreted in the milk of lac-
tating rats. A risk to the breast- fed child therefore cannot be 
excluded. As a precautionary measure, the use of tofacitinib 
during breast- feeding is contraindicated.
A study of a small number of patients with UC taking tofac-
itinib observed healthy newborns, no foetal deaths or con-
genital malformations and spontaneous abortions appeared 
consistent with background risks in the USA.98 Similar data 
exist for RA and PsO.99
5. History of VTE events: in patients with a history of throm-
boembolic events initiation of a JAKi should be carefully 
evaluated based on the increased rates of VTEs in patients 
at risk for these events (see below under risks and adverse 
events). Increased VTEs, especially PE, have been observed 
in patients with cardiovascular risk factors treated with 10 mg 
tofacitinib two times a day53 54 indicating that also these (ar-
terial) risks require consideration. Patients with recurrent 
thromboembolic events will usually receive anticoagulation 
treatment likely counteracting the risk.
The safety and efficacy of JAKi is under investigation in juve-
nile patients but has not yet been established in persons <18 
years of age. For restrictions regarding patients >65 years of age 
see below.
Finally, JAKi have not been studied and, therefore, are not 
recommended in combination with bDMARDs or potent immu-
nosuppressive agents such as cyclosporine or tacrolimus because 
of the possibility of increased immunosuppression and increased 
risk of infection or lymphoma.
IV. Pretreatment screening and risk assessments
1. History and physical examination: Important patient de-
tails to obtain before starting therapy include a history 
and risk estimation of VTE, infections, TB, risk factors 
for hepatitis B and C, as well as usual medical consider-
ations such as comorbidities, cardiovascular risk factors 
and concomitant medications of relevance, for example, 
Cox 2 inhibitors, prednisone doses >7.5 mg daily or oral 
contraceptives.
The recommendation for patients over 70 years of age is a 
baricitinib dose reduction to 2 mg daily due to age- related re-
ductions in renal function. Moreover, EMA has restricted the 
use of tofacitinib in people older than 65 years also due to 
an increased risk of serious infections.94 No dose reduction is 
recommended for modest renal impairment with upadacitin-
ib and filgotinib therapy.
Baseline skin check for non- melanoma skin cancer (NMSC) 
in patients at risk and chest X- ray is also recommended, un-
less recently performed.
2. Routine laboratory testing that includes a full blood count 
(including a differential white cell count), liver enzymes (in 
particular transaminases), and renal function tests are rec-
ommended before starting JAKi. Baseline lipid levels are sug-
gested unless recently checked. No creatine phosphokinase 
(CPK) testing is needed.
3. Hepatitis B virus (HBV) testing for anti- HBs, anti- HBc, and 
HBsAg is recommended in all patients. Patients with evi-
dence of chronic HBV infection (ie, positive HBsAg) should 
avoid JAKi or treatment with biologics if possible. If not 
possible, then concomitant treatment or prophylaxis with an 
anti- viral (eg, entecavir, tenofovir or tenofovir alafenamide) 
should be undertaken alongside consultation with a hepatol-
ogist.100 For patients with evidence of prior HBV exposure 
(positive HBc antibody) and no evidence of active viral repli-
cation (ie, negative HBsAg), a baseline HBV DNA should be 
obtained to rule out occult active HBV infection. If positive, 
then patients have active HBV and should be managed ac-
cording to the above. The main virological event of concern 
in these anti- HBc positive patients is HBsAg reappearance 
(seroreversion), consistently associated with hepatitis flare; 
HBV DNA detection (without HbsAg) leads to seroreversion 
and hepatitis in 50% of cases.100 If HBV- DNA negative, then 
such patients can start JAKi and should be routinely moni-
tored for HBV DNA and HBsAg reappearance (serorever-
sion) in line with respective national recommendations for 
TNFi. If HBV DNA or HBsAg subsequently turns positive 
during monitoring, then the patient should be managed as 
above with referral to a hepatologist for treatment. The JAKi 
should be temporarily stopped until full evaluation can be 
made. Concurrent treatment with an antiviral is possible, 
and the JAKi can be reinstituted once anti- viral therapy has 
been started.101
Hepatitis C virus (HCV) antibody testing is recommended 
and should be further assessed if positive, that is, HCV RNA 
testing. If positive, then the patient has active HCV and 
should be referred for treatment. In such case, JAKi should 
be withheld until HCV treatment has been completed.
4. HIV testing is recommended for those with HIV risk factors.
5. As the risk for TB- reactivation with JAKi is similar to that 
for TNFi, screening for TB is recommended, unless already 
done prior to bDMARD commencement without a risk of 
exposure since then. All patients in JAKi phase 3 studies were 
screened for TB and patients with active TB excluded while 
patients with latent TB were commenced on anti- TB thera-
py and included. Cases of TB were noted with JAKi more 
commonly than with placebo in pivotal trials, with at least 
some cases occurring in endemic areas likely representing 
newly acquired infection rather than reactivation of prior 
infection.12 93
6. Vaccination status should be sought. Country and regional 
vaccination guidelines should be followed. EULAR has re-
cently updated its vaccination recommendations for patients 
with autoimmune diseases.102 In addition to Herpes zoster 
reactivation, Herpes simplex and cytomegalovirus reactiva-
tion may also occur. HPV reactivation is not known to occur, 
but has not been evaluated systematically.
Herpes zoster reactivation: A history of varicella or zoster 
infection or immunisation should be obtained. Herpes zoster 
reactivation is clearly increased under JAKi with incidence 
rates (IRs) between 3–4 (Western Europe, USA, Australia) 
and 9 (Japan, Korea) per 100 patient- years compared with 
2–3 per 100 patient- years for TNFi. Risk factors include age, 
female gender, prednisolone >7.5 mg per day, infection and 
hospitalisation.11 12 103–106 As for serious infections, there is 
also a dose response for Herpes zoster reactivation. The reac-
tivation is likely based on the mode of action of JAKi block-
ing interferon pathways. If a patient develops Herpes zoster, 
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JAKi treatment should be temporarily interrupted until the 
episode resolves. A small proportion of patients can develop 
recurrent zoster. Antiviral prophylaxis could be considered 
in such individuals.
Evidence for the efficacy of the live Zostavax vaccine is 
questionable and as a live attenuated vaccine it necessitates 
a delay of 3–4 weeks postvaccination before starting a JAKi; 
further, a single missed dose of MTX could be considered, 
since MTX may blunt the antibody response,107 but this ap-
proach is not evidence based. In a live zoster vaccination 
study, zoster IRs at follow- up were numerically similar in the 
tofacitinib 5 mg and adalimumab and MTX arms but higher 
rates were seen for the combination of tofacitinib 5 mg two 
times a day with MTX.108 Notably, zoster rates at follow- up 
were generally similar in vaccinated versus non- vaccinated 
patients, but further studies are clearly needed. While the vac-
cination resulted in reasonable immune responses, 1 patient 
developed zoster infection having had no prior immunity.109
A new zoster vaccine has been more recently approved; be-
ing a nonlive vaccine, it is not contraindicated in patients 
receiving immunosuppressive or immunomodulating agents, 
but currently there are no data on safety and protective im-
munogenicity of this vaccine in patients treated with JAKi. 
As studies are underway, these questions should be resolved 
soon. The safety of the inactivated zoster vaccine (Shingrix) 
has been suggested by a small open label study of 400 pa-
tients with RA (no zoster activation, 6.7% disease flares, 
mostly mild, self- limiting, and not requiring therapeutic 
change), but efficacy and immunogenicity of the vaccine in 
this setting is unknown.110
7. Risk factors for VTEs111 112 should be considered by history 
and a potential clotting abnormality should be pondered in 
patients with a history of VTEs in whom such assessments 
have not yet been done. While these events are rare, the risks 
are increased in patients with prior VTEs; with increasing 
age (patients older than 65 years are at higher risk for having 
VTEs with tofacitinib); obesity (people with obesity have two 
times the risk of VTEs as people with normal weight, and the 
higher the weight, the higher the risk); prolonged immobility 
(ie, long travel, lower- extremity paralysis due to spinal cord 
injury, trauma with reduced mobility); hereditary (ie, factor 
V Leiden, prothrombin mutation 20210, etc) and acquired 
(ie, antiphospholipid syndrome, malignancy) thrombophilia; 
Cox 2 inhibitor therapy113 114; prednisolone of ≥7.5 mg/d 
and above; major surgical interventions, such as neurosurgic, 
urologic, gynaecologic and orthopedic surgery. Interestingly, 
a recent study from Sweden suggested that VTEs are signifi-
cantly related to disease activity with an adjusted RR of 1.99 
during high, 1.45 during moderate and 1.11 with low RA 
activity compared with remission.114 115 This potential rela-
tion between VTE rates and RA disease activity remains to 
be fully elucidated. For more details regarding VTEs and PEs 
see below under adverse events.
V. Adverse events
Adverse events are mainly related to the inhibition of cellular 
pathways and include those already mentioned above under 
risks. However, several other adverse events need more detailed 
consideration.
1. Serious infections including opportunistic infections such as 
TB and others, as well as reactivation of Herpes zoster and 
other viruses can occur. The IR of Herpes zoster reactivation 
amounts to about 3–4 compared with placebo (IR=1).115 116 
Their frequency is dose and co- medication dependent and 
the reactivation of Herpes zoster is more frequent than on 
bDMARDs and especially frequent in Japan and Korea. 
Moreover, EMA (but not FDA) has restricted the use of to-
facitinib in people older than 65 years due to an increased 
risk of serious infections.94 Herpes zoster was also seen with 
baricitinib and less commonly with upadacitinib. It is also 
listed as an important potential risk for filgotinib by EMA, 
and while they state that no signal for varicella zoster infec-
tion has been detected in the filgotinib RA clinical trial pro-
gram, the agency requests further evaluation by additional 
pharmacovigilance activities.117
2. Malignancy: The overall rates are not increased except for 
the risk of NMSC which might be elevated and, therefore, 
the task force recommends regular skin examinations, es-
pecially in countries with increased risk of NMSC, such as 
Australia. The task force also felt that current malignancy 
(except NMSC and cervical carcinoma in situ undergoing 
treatment) may be a contraindication for JAKi, but as stated 
previouly, this should be a shared decision making with the 
patient.
3. Anaemia and cytopenias: Anaemia of chronic disease, as 
usually seen in most IMIDs, does not improve on the group 
level with all JAKi except for filgotinib, and in some patients 
the pre- existing anaemia may deteriorate, presumably due to 
JAK 2 inhibition; JAK 2 is involved in EPO signalling (see 
figure 1). Cytopenias may occur but were not more frequent 
than on placebo,12 although with all JAKi a few patients may 
exhibit neutropenia and/or lymphopenia.
4. VTE/pulmonary embolism (PE). Across indications, in ran-
domised controlled trials and long term extensions of to-
facitinib followed for up to 9.5 years, no increased risk of 
VTE for the 5 mg bd dose has been seen.11 54 However, in 
a still ongoing safety study of patients with RA enriched for 
cardiovascular risk factors, a statistically significant PE im-
balance for tofacitinib 10 mg bd as compared with 5 mg two 
times a day was demonstrated with an absolute IR of 0.5 
for 10 mg and 0.3 for 5 mg53–55; compared with TNFi (ab-
solute IR of 0.1) which were investigated as a control arm, 
the PE risk thus being about threefold higher for the 5 mg 
dose and about sixfold higher for the 10 mg dose.54 94 In this 
same study, as reported by the EMA, VTE without PE were 
somewhat numerically higher with tofacitinib than TNFi but 
the difference was not statistically significant. Since this is an 
ongoing study, the full data for the 5 mg dose will have to be 
awaited for a full assessment of the VTE risk, but the 10 mg 
two times a day dose was discontinued in this study. A recent 
analysis of VTE/PE in clinical trials of UC in which most of 
the patients had been treated with a dose of 10 mg two times 
a day reported that during the placebo controlled period no 
UC patient had a VTE or PE and 1 VTE and 1 PE each were 
seen in placebo treated patients.118 During the long term, 
open- label extension comprising about 2400 patient- years 
of exposure, 1 patient had a VTE and 4 had PEs, all with 
risk factors for these events.118 The recent EMA assessment 
provided evidence for an increased PE risk at the 5 mg and 
especially the 10 mg two times a day dose of tofacitinib.55 
The FDA has not made a final determination and is awaiting 
the final, adjudicated results of the study.
Baricitinib at 4 mg had an imbalance in VTEs compared with 
the control arms (placebo or adalimumab) in the controlled 
period of RA trials; this has not been observed with the 2 mg 
dose.49 119 Risk factors were age, high BMI, immobilisation, 
surgery, use of Cox-2 inhibitors and a history of prior VTEs; 
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the risk may be up to 10- fold for patients with a history of 
VTEs and twofold for those patients taking Cox2 inhibi-
tors.120 Subsequently, there was no increase in risk when pa-
tients were transitioned from placebo or MTX to baricitinib 
as well as across long- term extension studies over 6 years 
but VTEs in the LTE were observed equally with 2 and 4 mg.
Numerically increased rates of VTEs have also been observed 
in the double blind phases of upadacitinib trials, primarily 
with the 15 mg once a day dose, although not in the head- to- 
head trial against adalimumab.49 58 119 With respect to filgo-
tinib, EMA regards VTE as a potential risk, but the agency 
also concluded that no increase in reports of VTEs was seen 
for filgotinib (100 mg and 200 mg doses) compared to pla-
cebo or comparators (MTX, ADA). Importantly, however, 
additional data by pharmacovigilance activities have been 
required by EMA.
Taken together, these observations elicited warnings (in some 
countries "black box" warnings) for VTE in the labels of all 
approved JAKi, plus additional warnings issued by the reg-
ulators (see above). In particular, the EMA recommends the 
use of tofacitinib in patients with RA ‘above the age of 65 
only when there is no alternative treatment’.53 55 Such age 
considerations have not been set in place for other JAKi that 
have similar VTE warnings in their label; however, data on 
outcomes studies in patients with cardiovascular risk factors 
are not available for those other agents. VTEs on baricitin-
ib also occurred in patients with risk factors, such as obe-
sity, and several continued therapy, although mostly under 
anticoagulation.120
While the overall risk of VTE is age dependent and in the 
order of 1:100–1:1000 (occurrence rate 0.25/100 patient 
years), this risk is about doubled in patients with RA.55 
Further research is needed to delineate the mechanisms how 
JAKi increases VTE rates (and how this compares to patients 
with RA in general), while we also lack understanding how 
glucocorticoids, Cox2 inhibitors, oral contraceptives, tamox-
ifen, thalidomide, antipsychotics elevate VTE risk. In any 
event, careful consideration should be given as whether or 
not to start a JAKi in any patient who may be at risk for a 
VTE.
With respect to major adverse cardiovascular events (MACE) 
across indications, in randomised controlled trials and long- 
term extensions no increased risks have been observed. As 
indicated above, a long- term study of tofacitinib in RA pa-
tients with cardiovascular risks is ongoing and has hitherto 
not shown evidence for an increase in MACE (regarding in-
crease in VTEs see above).
5. Laboratory abnormalities without clinical sequelae in the 
majority of patients: CPK elevations are occasionally seen 
without weakness, thus far with occasional myalgia,121 122 
but usually without clinical repercussions, although one pa-
tient has had rhabdomyolysis.123 Thus, in the rare event of 
symptoms, CPK should be tested, although in general this is 
not necessary. While the underlying cause is unknown and 
there have been suggestions this may be due to a renal tu-
bular effect, there are some data suggesting this effect might 
be due to restoration of muscle development with associated 
CPK elevations (an event that is suppressed by oncostatin M 
whose signalling depends on JAKs).124 125 Creatinine increas-
es have also been observed but without organ dysfunction or 
other clinical sequelae, such as hypertension.
Finally, gastrointestinal perforation has been reported in clin-
ical trials and may be a risk of bariticitinb and tofacitinib126 (and 
possibly other JAKi). Thus, JAKi should be used with caution in 
patients who may be at increased risk for gastrointestinal perfo-
ration (eg, patients with a history of diverticulitis and taking 
concomitant NSAIDs or glucocorticoids). Patients presenting 
with new onset abdominal signs and symptoms should be evalu-
ated promptly for early identification of gastrointestinal perfo-
ration knowing fever and elevation of acute phase reactants may 
be blunted by JAKi therapy.
VI. Laboratory and clinical monitoring during follow-up
1. As a minimal laboratory monitoring during follow- up, the 
task force recommends measurement of full blood count and 
differential, transaminases, renal function, at 1 month and 3 
months and then periodically such as every 3 months plus 
lipid levels just at 3 months.
Blood count: Haemoglobin change of less than or equal to 
20g/L decrease and haemoglobin levels greater than or equal 
to 90g/L do not require dose adjustment. Greater than a 
20g/L decrease or a haemoglobin of less than 80g/L (con-
firmed by repeat testing) should lead to dose interruption 
until haemoglobin values have normalised. Filgotinib leads 
to small dose dependent average increase in haemoglobin 
levels, compared with all other JAKi.
Absolute neutrophil counts over 1000/mm3 require no dose 
adjustment, however, a count of 500–1000/mm3 on two 
sequential measures suggest dose reduction or temporary 
cessation until count above 1000/mm3 when JAKi can be 
recommenced.
Absolute lymphocyte counts over 750/mm3 require no dose 
adjustment, a count of 500–750/mm3 on two sequential 
measures suggests a dose reduction or temporary cessation 
until the count is greater than 750/mm3 to allow recom-
mencement. There is some evidence that lymphocyte counts 
below 500/mm3 significantly increase the risk of opportun-
istic infection.
Liver function tests: Transaminases should be periodically 
monitored. Tofacitinib should not be used in severe hepatic 
impairment (Child Pugh C) nor should upadacitinib. Mild 
hepatic impairment (Child Pugh A) requires no dose adjust-
ment. In case of moderate hepatic impairment (Child Pugh 
B) the tofacitinib dose should be reduced to 5 mg once a day.
Renal function: Creatinine should be assessed periodical-
ly. In mild to moderate chronic renal impairment (CrCL 
50–80 mL/min) no dose adjustment is needed; with CrCL 
30–60 mL/min, baricitinib should be reduced to 2 mg daily. 
With severe renal impairment (CrCl <30 mL/min) tofacitinib 
dose should be reduced to 5 mg once daily and baricitinib not 
used at all.
Acute phase reactants: For evaluation and definition of re-
sponse be aware that CRP and ESR may be reduced inde-
pendently of reduction of disease activity and, therefore, 
consideration should be given to the use of disease activity 
scores that do not include inflammatory markers (such as 
CDAI in RA; see below under 3).
Lipid levels should be assessed approximately 3 months after 
JAKi commencement and if increased should be managed ac-
cording to national guidelines.
2. Consideration should be given to an annual formal skin check 
as evidence suggests an increased risk of NMSC with tofac-
itinib, possibly due to prior exposure to MTX and TNFi.127
3. Disease activity should be monitored regularly using vali-
dated composite measures of disease activity that include 
joint counts in order to assess if improvement by >50% was 
seen within 3 months and the treatment target by 6 months 
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(treat- to- target),128 129 in line with current management rec-
ommendations for RA and PsA,2 44 and in line with recom-
mendations for other IMIDs, respectively. It should be borne 
in mind that acute phase reactant levels may be reduced by 
JAKi independent of clinical improvement and, therefore, 
scores that are heavily weighted on acute phase reactants, 
such as the DAS28, should not be used for follow- up.130
Consideration of patient preferences
In rheumatology, there is still a substantial number of patients 
with suboptimal outcomes or who are faced with uncontrollable 
disease symptoms. They fail to respond adequately to existing 
DMARDs. Therefore, the advent of DMARDs with a new mode 
of action is welcome. The oral route may enable some patients 
to become more independent from hospital or health profes-
sionals compared with subcutaneous injections or infusions and 
also appeals to those with a needle phobia; on the other hand, 
some biological agents are only administered monthly or even 
less frequently and this may be seen as an advantage compared 
with taking a drug once or twice daily. Cost considerations are 
an overarching principle in RA treatment recommendations 
and thus part of treatment decisions; while the costs of JAKi 
are currently usually higher than those for biosimilars, this may 
change once these drugs become generic. Careful consideration 
of initiation and open communication with the patient are 
warranted. The prescription of JAKi may not be at the expense 
of attention to safety risks and must be in line with existing 
specialty guidelines for management and good clinical practice 
which also includes the need for regular laboratory monitoring 
even in patients receiving JAKi monotherapy. These points to 
consider contain important information for patients. A patient 
version or a decision tool will support patients to weigh poten-
tial benefits, harms and their personal goals and preferences, 
and subsequently strengthen their role in the decision- making 
process.
Research agenda
The committee felt that many questions remained open and 
needed to be addressed in future research in both adult and 
paediatric populations. These questions are pertinent to all JAKi 
and are presented in box 1.
DISCUSSION
Similar to the situation with bDMARDs 15–20 years ago, real- 
world experience with JAKi is limited. Therefore, this task 
force was formed which consisted of experienced clinical trial-
ists and people involved in treating patients with IMIDs across 
several medical areas and across nations and continents as well 
as patients and a health professional. The task force set out to 
provide the readers with comprehensive guidance on the use 
of this novel class of targeted therapies regarding efficacy and 
safety, based on evidence and complemented by expert opinion. 
In this consensus statement points to consider are provided for 
the use of JAKi across IMIDs for which they are approved or 
may be approved in the near future.
The consensus statement is designed to support physicians 
and other health professionals treating patients with IMIDs 
as well as patients themselves and other stakeholders, such as 
hospital administrators and payers, with an up- to- date summary 
on the thoughtful application of JAKi. Where there is occa-
sional redundancy in the paper, it derives from the fact that 
certain pieces of information relate to more than one chapter 
of this consensus statement, thus allowing readers who only 
focus on selected portions to obtain pertinent information. 
Currently baricitinib, filgotinib (in Europe and Japan), pefi-
citinib (in Japan), tofacitinib and upadacitinib are licensed for 
one or more autoimmune inflammatory diseases. The consensus 
statement is primarily based on the evidence derived by an SLR43 
from clinical trials and some observational studies, whereby 
safety aspects can currently be primarily or solely derived from 
information of the controlled and extended trial periods of the 
drugs.
Indeed, efficacy data from comprehensive clinical trial 
programmes but hardly any long- term registry data from clin-
ical practice are available on safety aspects . However, trial effi-
cacy and safety data are constantly being expanded, as are the 
indications. At present five available JAKi are approved for use 
in RA patients, but tofacitinib is already licensed for PsA and 
UC and other compounds will also likely receive approval for 
a range of indications. Thus, JAKi may arrive at a similarly 
Box 1 Research agenda
1. What is the efficacy and safety of switching between JAK- 
inhibitors in non- responders or due to lack of tolerability?
2. What are the predictors of response to JAK- inhibitors as 
compared to other DMARDs used for RA?
3. What is the effect of JAK- inhibitors on comorbidities of 
IMIDs including cardiovascular disease and osteoporosis?
4. Is VTE a class effect or a JAK inhibition effect and what is 
the mechanism of VTE? What is the actual risk of VTE when 
treating with a JAK- inhibitor? Is the effect confined to RA or 
observed in other indications?
5. What is the long- term safety from real- world data for JAK- 
inhibitors? For which patients should JAK inhibitors be 
contraindicated on basis of risk (particularly for VTE), and 
should prophylaxis be considered?
6. What is the safety of JAK- inhibition in patients with prior, 
current or who develop a malignancy whilst on therapy?
7. Are JAK- inhibitors effective and safe as therapy for 
autoimmune diseases induced by checkpoint inhibitors in 
patients with malignancy?
8. How safe are JAK- inhibitors in Hepatitis B, C, SARS- CoV-2 
infected patients and also other viral infections?
9. How safe are JAK- inhibitors in pregnancy and lactation? 
What should be recommended if a woman taking a JAK- 
inhibitor becomes pregnant?
10. Safety of JAK- inhibitors in elective surgery—should they be 
discontinued and if so for how long and when should they 
be restarted?
11. What is the efficacy of JAK- inhibitors in extra- articular 
RA manifestations including vasculitis, nodulosis, overlap 
syndromes?
12. What is the efficacy of JAK- inhibitors in connective tissue 
diseases such as SLE, inflammatory myositis and systemic 
sclerosis?
13. What is the efficacy and safety of combination therapies 
with JAK- inhibitors and bDMARDs in patients with severe 
RA or other diseases?
14. What are the molecular in vivo down- stream effects of JAK- 
inhibition in the setting of individual diseases?
15. What are the differences between different JAK- inhibitors 
regarding efficacy and safety?
16. What is safety of JAK inhibitors in patients over 65 years?
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broad or even broader list of indications across IMIDs as TNF- 
blockers. However, their broad efficacy is unrelated to inhibition 
of TNF signalling, but rather due to the fact that the intracellular 
blockade of JAKs relates to cytokines that are distinctly involved 
in different IMIDs, such as IL-6 in RA, IL-23 in PsA, PsO and 
IBD, or interferons in other diseases. Moreover, even if none 
of the cytokines activating the JAK- STAT pathway is known to 
be of significance in the pathogenesis of a particular disease, 
such as axial spondyloarthritis, it is possible that there are syner-
gistic inhibitory effects by interfering with signalling of several 
cytokines that individually are only minimally pathogenetically 
relevant, culminating in clinical efficacy. Moreover, JAKi also 
interfere with the consequences of JAK activation induced by 
cytokines that do not directly use the JAK- STAT pathway for 
signalling, such as TNF, which can activate IL-6 and interferons 
downstream of their primary effects, thus affecting various 
pathogenic pathways.39
There are some differences between the drugs which are due 
to different selectivities regarding JAKi when looking at both in 
vivo and in vitro data, spanning from predominant JAK1 inhibi-
tion (filgotinib) to pan- JAKi (peficitinib, tofacitinib); these may 
translate into differences in reversible cytokine inhibition over 
the dosing period. These differences will be dose dependent19 
and may be reflected in variability in safety but also aspects of 
efficacy.
Recommendations on indications and dosages can easily be 
derived from the clinical trials and labels of the respective drugs 
as stipulated by regulators, but the presumably more important 
items within this consensus statement relate to contraindications, 
pretreatment screening, safety and risks as well as monitoring and 
follow- up examinations. All these items have been addressed. 
The recommendations may change once further pharmacovigi-
lance and registry data become available. They may also change 
once more information becomes known regarding pathways to 
disease or pathways leading to adverse events. Of note, the task 
force was informed by, and developed its recommendations based 
on, a detailed SLR evaluating studies that were published until 
the end of 2018; however, since then additional safety aspects 
became known from information provided by regulators, but the 
trial(s) on which this new safety information is based have not 
yet been published. Thus, the task force went beyond the data 
provided in the SLR and addressed publications and regulatory 
communications that appeared after the end of the SLR period 
to provide readers with the most up- to- date material.
Among the adverse events, some have been expected from 
knowledge regarding blockade of cytokines that use JAK- STATs 
for signalling, such as an increased risk of serious (including 
opportunistic) infections. Others go beyond expectations but are 
explained by the pharmacologic effects of the drugs, such as the 
increase in herpes zoster rates. The failure to reverse anaemia 
of chronic disease would also be in line with expectations based 
on inhibition of JAK2, and this conclusion is confirmed by the 
improvement of anaemia when a more selective JAK1 inhib-
itor is applied.131 However, even if relatively rare and associ-
ated with known risk factors, the occurrence of VTEs and PEs 
is an unexpected and hitherto unexplained event requiring 
further information and elucidation. It is not clear if idiosyn-
cratic platelet activation, changes in procoagulant or fibrinolytic 
activity, or abnormal endothelial activation might be involved. 
However, other tyrosine kinase inhibitors may activate proco-
agulant activity132 which might be related to changes in lipids or 
lipoprotein levels.133 During the deliberations of the task force, 
comments arose that the control arms of some pivotal studies 
had an unusually low IR of VTEs; nonetheless, it is the nature 
of randomised controlled trials that the risk should be balanced 
across study arms and if one arm differs, one may conclude that 
the results are a consequence of the respective treatment. Further 
research activities in this area are urgently needed.
Since the time of the SLR, the task force meetings and the 
start of preparing this manuscript, the COVID-19 pandemic has 
struck the world. Many patients with IMIDs who are treated 
with bDMARDs or JAKi have contracted this viral disease. 
Currently, there is insufficient knowledge about the risks (or 
potential benefits) of immunomodulating drugs in these patients 
in either altering susceptibility to infection, or in determining 
disease progression once infected with SRAS- CoV2. Case reports 
and individual centre’s experiences do not yet suggest that these 
patients are at increased risk of having an adverse outcome of 
COVID-19. However, as yet no systematic analyses have been 
performed to inform physicians whether JAKi therapy may be 
continued or should be stopped prior to or during infection. 
Regardless, since these patients may be at an increased risk, 
primary prevention should be stressed with rigorous application 
of recommended public health and behavioural measures applied, 
including physical distancing, wearing masks and hygienic 
measures as recommended by most governments worldwide. 
Prophylactic discontinuation of an effective anti- inflammatory 
or immune modulatory therapy is not recommended at this 
time.134–136 However, if therapy has been temporarily ceased 
in IMID patients with proven COVID-19 infection, when to 
safely recommence therapy is also not known for patients that 
have recovered. It is suggested that when oropharyngeal PCR 
swabs are negative virus shed after a further 7 days may be 
non- viable.137
To better understand the consequences of COVID-19 on 
IMID patients with and without specific therapies, it is critical 
to enter patients infected with SARS- CoV2 into relevant regis-
tries and several exist.138–140 Of note, JAKi has been suggested 
to be potentially beneficial against COVID-19, particularly in 
the context of the cytokine release syndrome like hyperinflam-
mation which occurs in a small subset of patients, and several 
trials are currently ongoing to learn whether this approach has 
positive, negative or neutral effects.141–144 A rationale for the 
potential efficacy of baricitinib has been recently provided by 
Stebbing et al and based on predicted interference with viral 
trafficking.145 However, answers to the clinical validity of these 
hypotheses must come from observational studies as well as 
properly performed clinical trials.
In summary, JAKi are a new class of agents for the treatment 
of a variety of IMIDs with efficacy in many indications that is at 
least as good as that of bDMARDs and with an acceptable safety 
profile. Given their non- protein nature, antidrug antibodies and 
thus a potential secondary loss of efficacy would not occur. It 
is anticipated that based on these qualities and on the fact that 
they can be taken by the oral route their use will significantly 
increase over time. The presented consensus statement may be 
particularly helpful to those prescribing these drugs who aim to 
achieve the most appropriate and optimal use of these therapies.
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